Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 136790-76-6] Lubiprostone

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0679
Brand:	MCE
CAS:	136790-76-6

Overview

MDL	MFCD20268389
Molecular Weight	390.46
Molecular Formula	C20H32F2O5
SMILES	O=C(C(F)(F)CCCC)CC[C@@H]([C@@H](C1)O)[C@H](C1=O)CCCCCCC(O)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Dig Dis Sci. 2019 Sep;64(9):2527-2537.

Summary

Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation. Target: Others Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM). From Wikipedia.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01085643	Cedars-Sinai Medical Center\|Takeda Pharmaceuticals North America, Inc.	Constipation-predominant Irritable Bowel Syndrome	March 2010	Not Applicable
NCT00662363	Shirley Ryan AbilityLab\|Takeda Pharmaceuticals North America, Inc.	Constipation	April 2008	Not Applicable
NCT01447849	Texas Tech University Health Sciences Center, El Paso	Constipation	August 2011	Phase 2\|Phase 3
NCT01372423	Anchen Pharmaceuticals, Inc\|Novum Pharmaceutical Research Services	Chronic Idiopathic Constipation	May 2011	Phase 3
NCT00934479	Mayo Clinic\|Arizona State University\|Takeda Pharmaceuticals North America, Inc.	Other Constipation\|Irritable Bowel Syndrome	April 2010	Phase 1
NCT02481947	Braintree Laboratories	Chronic Idiopathic Constipation	May 2015	Phase 3
NCT00399542	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Irritable Bowel Syndrome\|Constipation	May 2005	Phase 3
NCT04361656	Ascension South East Michigan	Colonoscopy Preparation	May 1, 2020
NCT01993875	Mallinckrodt\|Sucampo Pharma Americas, LLC\|Takeda\|Sucampo AG	Chronic Idiopathic Constipation	October 2013	Phase 3
NCT01166789	University of North Carolina, Chapel Hill\|Takeda	Irritable Bowel Syndrome	February 2008	Phase 1
NCT01469819	Texas Tech University Health Sciences Center, El Paso\|Takeda Pharmaceuticals North America, Inc.	Chronic Idiopathic Constipation	June 2012	Phase 2\|Phase 3
NCT01170039	Emory University	Constipation\|Diabetes	September 2010	Phase 4
NCT00689026	Augusta University\|Takeda Pharmaceuticals North America, Inc.	Diabetes Mellitus, Type 1\|Diabetes Mellitus, Type 2	May 2008	Not Applicable
NCT00597428	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Opioid-Induced Bowel Dysfunction	August 2007	Phase 3
NCT03097861	Sucampo Pharma Americas, LLC\|Sucampo AG\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Chronic Idiopathic Constipation	March 13, 2017	Phase 3
NCT02695719	Takeda	Chronic Idiopathic Constipation	April 14, 2016	Phase 3
NCT00953043	Mayo Clinic\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Center for Research Resources (NCRR)\|Takeda	Healthy	September 2007	Phase 4
NCT01298219	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Opioid-induced Bowel Dysfunction	December 2010	Phase 3
NCT01096290	University of South Alabama\|Takeda\|Sucampo Pharmaceuticals, Inc.	Constipation	April 2010	Phase 4
NCT02651155	Takeda	Constipation	March 2, 2016	Phase 3
NCT01674530	Dr. Reddy´s Laboratories Limited\|Parexel	Chronic Idiopathic Constipation	October 2012	Phase 3
NCT01162863	University of Michigan\|Takeda Pharmaceuticals North America, Inc.	Irritable Bowel Syndrome\|Constipation	November 2010	Not Applicable
NCT01839734	Ruth M. Rothstein CORE Center	HIV	June 2013	Phase 2
NCT00844831	University of Louisville\|Takeda	Constipation	May 2009	Phase 4
NCT00595946	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Opioid-Induced Bowel Dysfunction	August 2007	Phase 3
NCT00380250	Sucampo Pharma Americas, LLC\|Takeda\|Mallinckrodt	Irritable Bowel Syndrome With Constipation	May 2005	Phase 3
NCT01236534	University of Rochester\|Takeda	Multiple Sclerosis\|Constipation	November 2010	Phase 4
NCT04138004	Rajavithi Hospital	Indication for Modification of Patient Status (Diagnosis)	December 1, 2019	Phase 4
NCT02544152	Sucampo Pharma Americas, LLC\|Takeda\|Sucampo AG\|Mallinckrodt	Irritable Bowel Syndrome	February 2015	Phase 2
NCT00706004	University of Arkansas\|Takeda Pharmaceuticals North America, Inc.	Constipation\|Cystic Fibrosis	July 2008	Not Applicable
NCT03010631	Sucampo Pharma Americas, LLC\|Takeda\|Mallinckrodt	Healthy Volunteers	November 16, 2016	Phase 3
NCT02138136	Sucampo Pharma Americas, LLC\|Takeda\|Mallinckrodt	Constipation - Functional	February 26, 2014	Phase 3
NCT01324284	Asian Institute of Gastroenterology, India	Colorectal Carcinoma	March 2011	Phase 3
NCT00953017	Brooke Army Medical Center	Colonoscopy	July 2009	Phase 4
NCT01460225	Dartmouth-Hitchcock Medical Center\|Takeda Pharmaceuticals North America, Inc.	Chronic Idiopathic Constipation	September 2007	Phase 4
NCT02766777	Sucampo Pharma Americas, LLC\|Sucampo AG\|Mallinckrodt	Constipation - Functional	April 12, 2016	Phase 3
NCT00620061	Sucampo Pharma Americas, LLC\|Mallinckrodt	Opioid-Induced Bowel Dysfunction	December 2007	Phase 3
NCT00452335	Sucampo Pharma Americas, LLC\|Sucampo Pharmaceuticals, Inc.\|Mallinckrodt	Constipation	January 2007	Phase 4
NCT00669461	University of Arkansas\|Takeda	Constipation\|Parkinson´s Disease	June 2009	Not Applicable
NCT02042183	Sucampo Pharma Americas, LLC\|Sucampo AG\|Mallinckrodt	Constipation - Functional	December 13, 2013	Phase 3
NCT01190020	Augusta University\|Takeda Pharmaceuticals North America, Inc.	Chronic Constipation, Methanogenesis	February 2009	Phase 1
NCT03720613	BioDelivery Sciences International\|HealthCore, Inc.	Opioid-induced Constipation	January 4, 2019
NCT02729909	Takeda	Constipation	May 11, 2016	Phase 3
NCT05144295	Alexandria University	Clinical Efficacy\|Treatment Efficacy\|Drug Side Effect	January 1, 2022	Phase 3
NCT00746395	University of South Alabama\|Takeda\|Sucampo Pharmaceuticals, Inc.	Inflammatory Bowel Disease	April 2008	Phase 4
NCT00645801	Henry Ford Health System\|Takeda Pharmaceuticals North America, Inc.	Colonoscopy	March 2008	Phase 4
NCT00908076	Baylor College of Medicine\|University of South Florida	Parkinson´s Disease	February 2009	Phase 4
NCT00611442	Brooke Army Medical Center\|Takeda	Bowel Preparation for Colonoscopy	October 2007	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 256.11 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5611 mL	12.8054 mL	25.6108 mL
5 mM	0.5122 mL	2.5611 mL	5.1222 mL
10 mM	0.2561 mL	1.2805 mL	2.5611 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3.25 mg/mL (8.32 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 3.25 mg/mL (8.32 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3.25 mg/mL (8.32 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] http://en.wikipedia.org/wiki/Lubiprostone

Synonyms

Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11α)-

(11α)-16,16-Difluoro-11-hydroxy-9,15-dioxoprostan-1-oic acid

RU 0211

Lubiprostone

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart